StockWatch
·

TORRENT PHARMACEUTICALS LTD.

BSE: 500420

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
4.1K
-0.1%+51.2%
Expenditure
3.4K
-0.1%+80.0%
Net Profit
498.00
+1.2%-16.6%
OPM %
37.66%
+0.33pp-0.68pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.001.2K2.3K3.5K4.6KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Revenue surge masks PAT decline; integration ongoing, base business resilient

JB integration · cost synergies · PAT erosion

TranscriptDeep diveQ2 FY2729 Oct 20266 minPharma & Healthcare

Torrent Pharma: consolidated PAT falls 9.6% YoY to ₹534 Cr despite 51% revenue surge

pharmaceuticals · jb chemicals merger · margin compression

ResultsQ2 FY2723 Oct 20263 minPharma & Healthcare

Merger momentum & margin accretion on deck — first full quarter post-JB integration

JB Chemicals merger · integration accretion · margin expansion

Result previewQ2 FY2717 Oct 20263 minPharma & Healthcare
Latest
Board Meeting23 Oct, 4:40 pm

Torrent Pharma: consolidated PAT falls 9.6% YoY to ₹534 Cr despite 51% revenue surge

Torrent Pharmaceuticals' consolidated (primary) Q2 FY27 revenue was ₹4,979 Cr, up 50.8% YoY and 1.2% QoQ, while PAT fell 9.6% YoY to ₹534 Cr (down 5.7% QoQ from ₹566 Cr). The headline revenue jump is largely inorganic: J.B. Chemicals, amalgamated into Torrent effective 8 July 2026 (NCLT-approved scheme, appointed date 21 January 2026), contributed ₹1,086 Cr of the ₹4,979 Cr total; the like-for-like base business grew a steadier 18% YoY to ₹3,893 Cr. Standalone PAT was ₹498 Cr, down a steeper 16.6% YoY — consolidated earnings held up relatively better because they capture JB's subsidiaries for the full quarter, while acquisition debt sits mostly at the standalone/parent level. Operating performance was actually strong: consolidated Op. EBITDA was ₹1,666 Cr, up 53.8% YoY, with margin expanding to 33.5% from 32.8%. The net margin compression (NPM 10.7% vs 17.9% YoY, 11.5% QoQ) sits entirely below the EBITDA line — finance costs jumped to ₹300 Cr from ₹48 Cr and depreciation & amortisation to ₹609 Cr from ₹204 Cr, both consequences of debt-funding the JB acquisition (consolidated debt-equity now 0.76x vs 0.31x) and amortising the ₹23,352 Cr of intangibles recognised on purchase accounting. Exceptional items were minor and roughly flat YoY, so adjusting for them barely moves the picture — adjusted PAT is still down about 9.9% YoY. The drag is structural (financing and amortisation), not a one-off. Against FY27 guidance set on the Q1 call — JB India Rx double-digit growth and international high-single to low-double-digit constant-currency growth — the quarter missed on both: JB India Rx (ex trade generics/contrast media) grew just 7% YoY to ₹597 Cr (H1 at 10%, right on the guided line), and JB International revenue fell 7% YoY to ₹406 Cr. Base EBITDA margin improved ~70bps YoY, broadly in line with the guided ~50bps annual pace. No quarter-specific street PAT/revenue consensus could be confirmed via search; against the pre-result preview's EBITDA margin expectation of 24-26%, the actual 33.5% Op. EBITDA margin beat that marker comfortably. Base India revenue grew 20% YoY against 12% IPM growth (PharmaTrac), and Brazil grew 38% reported (20% constant currency) against 6% market growth — both ahead of market. The quarter also saw an Executive Director resignation on 16 October, just before results, continuing the management churn flagged pre-result, plus a further ₹11.88 Cr investment in Torrent Urja (power/capex). Management's own framing, from the results press release, is that India base-business strength (+20%) was offset by a "transient impact on JB business" from post-merger integration — consistent with the India Rx and international shortfalls against guidance.

23 Oct 2026, 04:40 pm

Corporate Events

Board MeetingTORNTPHARM
2026
23Oct

Board Meeting

A meeting of the Board of Directors will be held on Friday, …

BSE Filing ↗
Board MeetingTORNTPHARM
2026
30Sep

Board Meeting

The Board approved the Audited Standalone Financial Results …

BSE Filing ↗
Board MeetingTORNTPHARM
2026
30Jul

Board Meeting

A meeting of the Board of Directors will be held to consider…

BSE Filing ↗
Board MeetingTORNTPHARM
2026
23Jun

Board Meeting

The 53rd Annual General Meeting (AGM) of Torrent Pharmaceuti…

BSE Filing ↗
DividendTORNTPHARM
2026
29May

₹9 / share

BSE Filing ↗
DividendTORNTPHARM
2026
29May

₹29 / share

BSE Filing ↗
Board MeetingTORNTPHARM
2026
28Apr

Board Meeting

Meeting of equity shareholders to consider and approve the p…

BSE Filing ↗
DividendTORNTPHARM
2026
13Feb

₹26 / share

BSE Filing ↗
Board MeetingTORNTPHARM
2026
13Feb

Board Meeting

Consider and approve Audited Financial Results, Consider and…

BSE Filing ↗
Board MeetingTORNTPHARM
2025
7Nov

Board Meeting

Consider and approve the Audited Financial Results on Standa…

BSE Filing ↗
Board MeetingTORNTPHARM
2025
28Jul

Board Meeting

Considering and approving the Audited Financial Results on S…

BSE Filing ↗
DividendTORNTPHARM
2025
20Jun

₹5 / share

BSE Filing ↗
Board MeetingTORNTPHARM
2025
20May

Board Meeting

Considering and approving the Audited Financial Results of t…

BSE Filing ↗
Board MeetingTORNTPHARM
2025
24Jan

Board Meeting

Consider and approve the Audited Financial Results on Standa…

BSE Filing ↗
Board MeetingTORNTPHARM
2024
25Oct

Board Meeting

Consider and approve the Audited Financial Results on Standa…

BSE Filing ↗
Board MeetingTORNTPHARM
2024
23Jul

Board Meeting

Consideration and approval of Audited Financial Results on S…

BSE Filing ↗
Board MeetingTORNTPHARM
2024
24May

Board Meeting

Consideration and approval of Audited Financial Results of t…

BSE Filing ↗
DividendTORNTPHARM
2024
23Feb

₹22 / share

BSE Filing ↗
Board MeetingTORNTPHARM
2024
2Feb

Board Meeting

Consideration and approval of Audited Financial Results on S…

BSE Filing ↗
Board MeetingTORNTPHARM
2023
23Oct

Board Meeting

Consider and approve Audited Financial Results on Standalone…

BSE Filing ↗